论文部分内容阅读
麦迪霉素属大环内酯族抗生素。目前有肠溶片剂,胶囊剂,颗粒剂和静脉注射剂应用于临床。口服后麦迪霉素广泛分布于各组织中,血浓度低,有胃肠道反应。为开辟栓剂新品种,提高麦迪霉素用药后血浓度,扩大临床使用范围,克服药物对胃肠道的反应,我们结合苏州第三药厂开发新剂型的计划,对家兔进行口服、肛门栓剂给药后血浓度的对比。研究了四种基质以及二种促吸收附加剂促进麦迪霉素直肠吸收的情况。
Midecamycin is a macrolide antibiotic. At present, enteric-coated tablets, capsules, granules and intravenous injection are used clinically. After oral administration midecamycin is widely distributed in various tissues, low blood concentration, gastrointestinal reactions. In order to open up new varieties of suppositories, increase the blood concentration after using midecamycin, expand the scope of clinical use, and overcome the drug’s response to the gastrointestinal tract, we combined with the plan of developing a new dosage form of the third pharmaceutical company in Suzhou and conducted oral and anal suppositories Blood concentration after administration contrast. Four substrates and two absorption-promoting additives were studied to promote rectal absorption of mimdomycin.